Cargando…
A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer
BACKGROUND: Immune checkpoint inhibitors (ICI) have emerged as active therapies in the management of advanced RCC. While multiple studies have shown clinical activity of ICIs in clear cell histologies, the evidence to support their use in non-clear cell (ncc) subtypes is based on smaller prospective...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490428/ https://www.ncbi.nlm.nih.gov/pubmed/36212797 http://dx.doi.org/10.3233/KCA-210012 |
_version_ | 1784793083811987456 |
---|---|
author | Palma dos Reis, Ana Filipa Simão, Diana Odeny, Thomas Rodrigues, Chiara Fontes-Sousa, Mário da Luz, Ricardo Chowdry, Rajasree Pia Welsh, Sarah J. Paller, Channing Barata, Pedro C. |
author_facet | Palma dos Reis, Ana Filipa Simão, Diana Odeny, Thomas Rodrigues, Chiara Fontes-Sousa, Mário da Luz, Ricardo Chowdry, Rajasree Pia Welsh, Sarah J. Paller, Channing Barata, Pedro C. |
author_sort | Palma dos Reis, Ana Filipa |
collection | PubMed |
description | BACKGROUND: Immune checkpoint inhibitors (ICI) have emerged as active therapies in the management of advanced RCC. While multiple studies have shown clinical activity of ICIs in clear cell histologies, the evidence to support their use in non-clear cell (ncc) subtypes is based on smaller prospective trials and retrospective analyses. OBJECTIVE: The objective of this review is to summarize the clinical outcomes of ICI-based therapies in ncc-subtypes and in tumors with sarcomatoid/rhabdoid features. METHODS: We performed a systematic literature search using PubMed, Google Scholar and ASCO databases. The keywords “renal cell cancer” and “immune checkpoint inhibitors” and equivalents were used and all original publications between July 2016 and July 2021 were included. RESULTS: We included a total of 14 publications, including two clinical trials and 12 case series. The most frequent histologies were papillary (up to 75-100%), unclassified (up to 34%) and chromophobe (up to 28%). ICI monotherapy showed some activity in both 1st and 2nd line with response rates up to 27%. ICI combination regimens yielded better activity than ICI monotherapy but, overall, a heterogeneous efficacy was noted across histologies. Overall, outcomes of ICIs were superior in tumors with sarcomatoid/rhabdoid features. CONCLUSION: The observed activity of ICI-based therapies was heterogeneous. Combination regimens, papillary subtype and sarcomatoid/rhabdoid features were associated with higher responses. These findings might help treatment decisions and require further validation. |
format | Online Article Text |
id | pubmed-9490428 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | IOS Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-94904282022-10-05 A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer Palma dos Reis, Ana Filipa Simão, Diana Odeny, Thomas Rodrigues, Chiara Fontes-Sousa, Mário da Luz, Ricardo Chowdry, Rajasree Pia Welsh, Sarah J. Paller, Channing Barata, Pedro C. Kidney Cancer Systematic Review BACKGROUND: Immune checkpoint inhibitors (ICI) have emerged as active therapies in the management of advanced RCC. While multiple studies have shown clinical activity of ICIs in clear cell histologies, the evidence to support their use in non-clear cell (ncc) subtypes is based on smaller prospective trials and retrospective analyses. OBJECTIVE: The objective of this review is to summarize the clinical outcomes of ICI-based therapies in ncc-subtypes and in tumors with sarcomatoid/rhabdoid features. METHODS: We performed a systematic literature search using PubMed, Google Scholar and ASCO databases. The keywords “renal cell cancer” and “immune checkpoint inhibitors” and equivalents were used and all original publications between July 2016 and July 2021 were included. RESULTS: We included a total of 14 publications, including two clinical trials and 12 case series. The most frequent histologies were papillary (up to 75-100%), unclassified (up to 34%) and chromophobe (up to 28%). ICI monotherapy showed some activity in both 1st and 2nd line with response rates up to 27%. ICI combination regimens yielded better activity than ICI monotherapy but, overall, a heterogeneous efficacy was noted across histologies. Overall, outcomes of ICIs were superior in tumors with sarcomatoid/rhabdoid features. CONCLUSION: The observed activity of ICI-based therapies was heterogeneous. Combination regimens, papillary subtype and sarcomatoid/rhabdoid features were associated with higher responses. These findings might help treatment decisions and require further validation. IOS Press 2022-08-04 /pmc/articles/PMC9490428/ /pubmed/36212797 http://dx.doi.org/10.3233/KCA-210012 Text en © 2022 – The authors. Published by IOS Press https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Systematic Review Palma dos Reis, Ana Filipa Simão, Diana Odeny, Thomas Rodrigues, Chiara Fontes-Sousa, Mário da Luz, Ricardo Chowdry, Rajasree Pia Welsh, Sarah J. Paller, Channing Barata, Pedro C. A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer |
title | A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer |
title_full | A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer |
title_fullStr | A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer |
title_full_unstemmed | A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer |
title_short | A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer |
title_sort | systematic review of immune checkpoint inhibitors in non-clear-cell renal cancer |
topic | Systematic Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490428/ https://www.ncbi.nlm.nih.gov/pubmed/36212797 http://dx.doi.org/10.3233/KCA-210012 |
work_keys_str_mv | AT palmadosreisanafilipa asystematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer AT simaodiana asystematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer AT odenythomas asystematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer AT rodrigueschiara asystematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer AT fontessousamario asystematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer AT daluzricardo asystematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer AT chowdryrajasreepia asystematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer AT welshsarahj asystematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer AT pallerchanning asystematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer AT baratapedroc asystematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer AT palmadosreisanafilipa systematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer AT simaodiana systematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer AT odenythomas systematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer AT rodrigueschiara systematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer AT fontessousamario systematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer AT daluzricardo systematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer AT chowdryrajasreepia systematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer AT welshsarahj systematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer AT pallerchanning systematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer AT baratapedroc systematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer |